Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2011 1
2012 2
2013 2
2014 2
2015 1
2016 2
2017 1
2018 1
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
MDC1 Enhances Estrogen Receptor-mediated Transactivation and Contributes to Breast Cancer Suppression.
Zou R, Zhong X, Wang C, Sun H, Wang S, Lin L, Sun S, Tong C, Luo H, Gao P, Li Y, Zhou T, Li D, Cao L, Zhao Y. Zou R, et al. Int J Biol Sci. 2015 Jul 3;11(9):992-1005. doi: 10.7150/ijbs.10918. eCollection 2015. Int J Biol Sci. 2015. PMID: 26221067 Free PMC article.
In this study, we have identified MDC1 as a co-activator of ERalpha in breast cancer cells and demonstrated that MDC1 associates with ERalpha. ...MDC1 depletion led to the promotion of breast cancer progression, and the expression of MDC1 is lower in b …
In this study, we have identified MDC1 as a co-activator of ERalpha in breast cancer cells and demonstrated that MDC1 associat …
LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer.
Wang S, Zou Z, Luo X, Mi Y, Chang H, Xing D. Wang S, et al. Oncogene. 2018 Jun;37(24):3243-3259. doi: 10.1038/s41388-018-0193-4. Epub 2018 Mar 16. Oncogene. 2018. PMID: 29545602
Importantly, a LRH1-binding site mapped between -1812 and -1804 bp of the proximal MDC1 promoter was identified. Moreover, LRH1 and MDC1 mRNA levels were positively correlated in recurrent breast cancer samples. These results implied LRH1 enhanced breast cancer cell …
Importantly, a LRH1-binding site mapped between -1812 and -1804 bp of the proximal MDC1 promoter was identified. Moreover, LRH1 and …
JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks.
Watanabe S, Watanabe K, Akimov V, Bartkova J, Blagoev B, Lukas J, Bartek J. Watanabe S, et al. Nat Struct Mol Biol. 2013 Dec;20(12):1425-33. doi: 10.1038/nsmb.2702. Epub 2013 Nov 17. Nat Struct Mol Biol. 2013. PMID: 24240613
JMJD1C was stabilized by interaction with RNF8, was recruited to DSBs, and was required for local ubiquitylations and recruitment of RAP80-BRCA1 but not 53BP1. JMJD1C bound to RNF8 and MDC1, and demethylated MDC1 at Lys45, thereby promoting MDC1-RNF8 interact …
JMJD1C was stabilized by interaction with RNF8, was recruited to DSBs, and was required for local ubiquitylations and recruitment of RAP80-B …
DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours.
Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, Stucki M, Jackson S, Lukas J, Bartek J. Bartkova J, et al. Oncogene. 2007 Nov 22;26(53):7414-22. doi: 10.1038/sj.onc.1210553. Epub 2007 Jun 4. Oncogene. 2007. PMID: 17546051
Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and MDC1 for tumour suppressors. Contrary to carcinomas, almost no activation or loss of MDC1 or 53BP1 were found among testicular ger …
Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and M …
Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study.
Brooks JD, Teraoka SN, Reiner AS, Satagopan JM, Bernstein L, Thomas DC, Capanu M, Stovall M, Smith SA, Wei S, Shore RE, Boice JD Jr, Lynch CF, Mellemkjaer L, Malone KE, Liang X; Wecare Study Collaborative Group; Haile RW, Concannon P, Bernstein JL. Brooks JD, et al. Hum Mutat. 2012 Jan;33(1):158-64. doi: 10.1002/humu.21604. Epub 2011 Sep 29. Hum Mutat. 2012. PMID: 21898661 Free PMC article.
The location-specific radiation dose received by the contralateral breast was estimated from radiotherapy records and mathematical models. One hundred fifty-two SNPs in six genes (CHEK2, MRE11A, MDC1, NBN, RAD50, TP53BP1) involved in the DNA DSBs response were genotyped. . …
The location-specific radiation dose received by the contralateral breast was estimated from radiotherapy records and mathematical models. O …
Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.
Sottnik JL, Bordeaux EK, Mehrotra S, Ferrara SE, Goodspeed AE, Costello JC, Sikora MJ. Sottnik JL, et al. Mol Cancer Res. 2021 Aug;19(8):1270-1282. doi: 10.1158/1541-7786.MCR-21-0025. Epub 2021 May 4. Mol Cancer Res. 2021. PMID: 33947745 Free PMC article.
Supporting this, in breast tumor tissue microarrays, MDC1 protein was frequently low or absent in IDC, but MDC1 loss was rare in ER(+) ILC. ER:MDC1 interaction and MDC1 coregulator functions may underlie ER function in ILC and serve as targets to overc …
Supporting this, in breast tumor tissue microarrays, MDC1 protein was frequently low or absent in IDC, but MDC1 loss was rare …
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
Baker LA, Holliday H, Roden D, Krisp C, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Sankaranarayanan G, Law AMK, McFarland A, Simpson PT, Lakhani S, Dodson E, Selinger C, Anderson L, Samimi G, Hacker NF, Lim E, Ormandy CJ, Naylor MJ, Simpson K, Nikolic I, O'Toole S, Kaplan W, Cowley MJ, Carroll JS, Molloy M, Swarbrick A. Baker LA, et al. Breast Cancer Res. 2020 Jun 11;22(1):63. doi: 10.1186/s13058-020-01306-6. Breast Cancer Res. 2020. PMID: 32527287 Free PMC article.
RESULTS: These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA damage checkpoint protein 1 (MDC1). Through MDC1, ID4 interacts with other DNA repair proteins (gammaH2AX and BRCA1) at fragile chromatin sites. ...Ana …
RESULTS: These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA damage checkpoint protein …
MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination.
Zhang F, Bick G, Park JY, Andreassen PR. Zhang F, et al. J Cell Sci. 2012 Dec 15;125(Pt 24):6049-57. doi: 10.1242/jcs.111872. Epub 2012 Oct 4. J Cell Sci. 2012. PMID: 23038782 Free PMC article.
Importantly, we offer the first insight into how BRCA1-dependent recruitment of PALB2 is integrated with other DNA damage signaling pathways. We find that PALB2 localization depends on the presence of MDC1, RNF8, RAP80 and Abraxas upstream of BRCA1. Thus, PALB2 may link HR …
Importantly, we offer the first insight into how BRCA1-dependent recruitment of PALB2 is integrated with other DNA damage signaling pathways …
Prediction of Overall Survival Among Female Patients With Breast Cancer Using a Prognostic Signature Based on 8 DNA Repair-Related Genes.
Zhang D, Yang S, Li Y, Yao J, Ruan J, Zheng Y, Deng Y, Li N, Wei B, Wu Y, Zhai Z, Lyu J, Dai Z. Zhang D, et al. JAMA Netw Open. 2020 Oct 1;3(10):e2014622. doi: 10.1001/jamanetworkopen.2020.14622. JAMA Netw Open. 2020. PMID: 33017027 Free PMC article.
RESULTS: In this prognostic study based on samples from 1096 women with BC (mean [SD] age, 59.6 [13.1] years), 8 DRGs (MDC1, RPA3, MED17, DDB2, SFPQ, XRCC4, CYP19A1, and PARP3) were identified as prognostic biomarkers. ...
RESULTS: In this prognostic study based on samples from 1096 women with BC (mean [SD] age, 59.6 [13.1] years), 8 DRGs (MDC1, RPA3, ME …
Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Watanabe Y, Maeda I, Oikawa R, Wu W, Tsuchiya K, Miyoshi Y, Itoh F, Tsugawa K, Ohta T. Watanabe Y, et al. Genes Cells. 2013 Dec;18(12):1120-30. doi: 10.1111/gtc.12100. Epub 2013 Oct 28. Genes Cells. 2013. PMID: 24581343 Free article.
The aberrant DNA methylation status of the following HR related-genes was analyzed using bisulfite-pyrosequencing: BRCA1, BRCA2, BARD1, MDC1, RNF8, RNF168, UBC13, ABRA1, PALB2, RAD50, RAD51, RAD51C, MRE11, NBS1, CtIP and ATM. ...
The aberrant DNA methylation status of the following HR related-genes was analyzed using bisulfite-pyrosequencing: BRCA1, BRCA2, BARD1, M …
17 results